Lorigerlimab - MacroGenics
Alternative Names: AEX1344; EXPASY; MGD-019; PD-1 x CTLA-4 bispecific DART moleculeLatest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator MacroGenics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
- Phase I/II Solid tumours
Most Recent Events
- 12 Dec 2024 MacroGenics plans a phase II trial for Solid tumors (Late-stage disease, Second-line therapy or greater) in March 2025 (IV) (NCT06730347)
- 06 Nov 2023 Macrogenics plans a phase I/II trial for Solid tumours (Combination therapy) in USA in 2024
- 28 Sep 2023 Phase-II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in United Kingdom, Spain, Puerto Rico, Poland, Georgia, France, Bulgaria, Belgium, USA (IV) (NCT05848011)